Please visit answersincme.com/860/102724337-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Charu Aggarwal, MD, MPH, FASCO; and Benjamin Levy, MD, FASCO. In this activity, expert oncologists will engage in a case-based discussion examining how current guidelines and evidence inform the use of frontline immunotherapy-based regimens in the management of metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Review the latest evidence for IO-based regimens in first-line metastatic NSCLC; Apply evidence-based approaches to select IO-based regimens for first-line metastatic NSCLC, based on patient types; Propose workflows that ensure timely biomarker testing and minimize delays in initiating optimal IO-based therapy; and Outline strategies to manage common and serious AEs associated with preferred first-line IO-based regimens, without losing disease control.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related